---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-051461"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:14:32.459895+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Madrigal appoints Jackie Fouse to Board; Fred Craves to retire in July 2025

## Summary
- Fred Craves, Ph.D. resigns from Madrigal's Board effective July 1, 2025; no disagreement cited.
- Board expanded to 10 members; Jacqualyn Fouse, Ph.D. elected to fill new vacancy on March 10, 2025.
- Fouse to serve on Audit and Nominating & Governance Committees; receives annual cash retainer of $50,000 plus committee fees.
- Fouse granted $600,000 equity award (50% options, 50% RSUs) vesting over two years; prorated annual director award also granted.
- Fouse is former CEO of Agios Pharmaceuticals and current Chair of Agios Board; over 30 years healthcare experience.

## SEC filing metadata
- accession: 0001193125-25-051461
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312525051461/0001193125-25-051461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312525051461/d916063d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-051461
- JSON: https://secwatch.observer/filing/0001193125-25-051461.json
- Plain text: https://secwatch.observer/filing/0001193125-25-051461.txt

## Key facts
- Executive change
  Fred Craves resigned as Director at MADRIGAL PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Director
  source text: On March 9, 2025, Fred Craves, Ph.D. provided notice of his resignation from the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”), effective as of July 1, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312525051461/0001193125-25-051461-index.htm
- Executive change
  Jackie Fouse was elected as Director at MADRIGAL PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Director
  source text: On March 10, 2025, following the recommendation of its Nominating and Governance Committee, the Board expanded the size of the Board from nine to ten members and elected Jackie Fouse, Ph.D. to fill the newly created vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312525051461/0001193125-25-051461-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.